Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00058838
Status:
COMPLETED
Last Update Posted:
2006-06-07
First Post:
2003-04-14
Brief Title:
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinsons Disease
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Double-Blind Placebo-Controlled Fixed-Dose Response Study Comparing the Efficacy and Safety of Sumanirole Versus Placebo in Patients With Early Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2006-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine whether sumanirole at three different dose levels is effective and safe in the treatment of the signs and symptoms of early Parkinsons disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None